Licensing · MENA · Announced 16 Aug 2026
Bio-Thera Solutions → Avalon Pharma
Licensing deal between Bio-Thera Solutions (China) and Avalon Pharma (Saudi Arabia), covering BAT2406, announced 16 Aug 2026. Value: Undisclosed.
Parties: Bio-Thera Solutions (China) → Avalon Pharma (Saudi Arabia)
- Deal type
- Licensing
- Value
- Undisclosed
- Territory
- Saudi Arabia + wider MENA
- Therapeutic area
- Immunology / Inflammation
- Asset
- BAT2406 — proposed dupilumab biosimilar (ref. Dupixent®)
- Announced
- 16 Aug 2026
Our analysis
Executive summary.
Bio-Thera has granted Avalon Pharma exclusive rights to register and commercialize BAT2406 — its proposed biosimilar of Sanofi/Regeneron's Dupixent (dupilumab) — across Saudi Arabia and the wider MENA region, on a renewable 15-year term . Bio-Thera keeps development, manufacturing and supply; Avalon takes regulatory approvals and commercialization, with rights to localize manufacturing in future. Launch is expected around 2031, subject to patent clearance — timed to Dupixent's patent cliff.
The full analysis is free to read with a work email on this page.
Source: Citeline/Generics Bulletin